TRDA - Latest News

Entrada Therapeutics, Inc. (TRDA), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $177.2M. Beta to the broader market is -0.24.

The article list below shows the most recent TRDA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent TRDA Headlines

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

globenewswire.com - Oct 14, 2026

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

globenewswire.com - Oct 14, 2026

-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were con

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

seekingalpha.com - Oct 10, 2026

Entrada Therapeutics is rated Buy with a $8. 50 fair value, offering ~52% upside from $5.

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

globenewswire.com - Sep 10, 2026

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the

BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA

defenseworld.net - Sep 4, 2026

BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc.

How News Affects TRDA Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track TRDA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked TRDA news questions

What is the latest TRDA news headline?

The most recent TRDA headline (Oct 14, 2026) is "Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the TRDA news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What TRDA news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual TRDA options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.